 SAN DIEGO, Jan. 19, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. Nasdaq: MTCR, a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food Drug Administration FDA has granted Fast Track designation to MET642, the companys second farnesoid X receptor FXR agonist, for the treatment of non-alcoholic steatohepatitis NASH. 